Metformin in combination with dasatinib further activated AMPK and induced EGFR degradation as well as apoptosis, implicating that induction of metabolic stress could mediate anti-tumor effect and serve as an anti-cancer strategy. The gene discussed is EGFR; the disease is cancer.